VRAX
Virax Biolabs Group LimitedNASDAQHealthcare$0.15-12.18%ClosedMarket Cap: $663,451
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
0.14
P/S
222.19
EV/EBITDA
0.39
DCF Value
$1.26
FCF Yield
-914.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
-8774.5%
Operating Margin
-196566.7%
Net Margin
-189001.7%
ROE
-102.5%
ROA
-98.8%
ROIC
-99.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 2026 | $1.6K | -13396.4% | $-2.6M | $-2.3M | $-0.49 | — |
| Q4 2025 | $1.4K | -3381.2% | $-3.3M | $-3.3M | $-0.76 | — |
| FY 2025 | $6.3K | -838.2% | $-6.2M | $-6.1M | $-1.95 | — |
| Q2 2025 | $5.0K | -130.7% | $-2.9M | $-2.8M | $-0.89 | — |
| Q4 2024 | $79.9K | 50.1% | $-3.8M | $-3.8M | $-1.71 | — |
| FY 2024 | $156.4K | 32.3% | $-6.5M | $-6.7M | $-3.36 | — |
| Q2 2024 | $76.5K | 13.7% | $-2.7M | $-2.9M | $-1.64 | — |
| Q4 2023 | $2.8K | -52.9% | $-4.3M | $-4.0M | $-2.58 | — |
| FY 2023 | $8.6K | -15.9% | $-5.7M | $-5.5M | $-5.13 | — |
| Q2 2023 | $5.8K | 2.0% | $-1.4M | $-1.4M | $-1.24 | — |
| Q4 2022 | $-92.9K | 207.6% | $-1.2M | $-1.2M | $-1.02 | — |
| FY 2022 | $0.00 | NaN% | $-1.7M | $-1.7M | $-1.50 | — |